amivantamab-vmjw,osimertinib,lazertinib
janssen,genmab,astrazeneca,yuhan corp
['chrysalis-2', 'lcsm,(-blcsm)', 'nsclc', 'lung', 'sclc']
#asco22 news: chrysalis and chrysalis-2 trial updates presented by &amp; , respectively support the use of #amivantamab in certain patients with advanced #nsclc. read our report here #lcsm #lungcancer 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.